1、Xiong Y, Li S, Wang C, et al. Chinese stroke association guidelines on reperfusion therapy for acute ischaemic stroke 2024. Stroke Vasc Neurol. Published online January 19, 2025. doi:10.1136/svn-2024-003977

2、Li S, Gu HQ, Feng B, et al. Safety and efficacy of intravenous recombinant human prourokinase for acute ischaemic stroke within 4·5 h after stroke onset (PROST-2): a phase 3, open-label, non-inferiority, randomised controlled trial. Lancet Neurol. 2025;24(1):33-41. doi:10.1016/S1474-4422(24)00436-8

3、Nguyen TN, Xiong Y, Li S, Abdalkader M, Chen HS. Current gaps in acute reperfusion therapies. Curr Opin Neurol. 2025;38(1):3-9. doi:10.1097/WCO.0000000000001337

4、Liu H, Jin A, Pan Y, et al. Efficacy and Safety of Intravenous Tenecteplase Versus Alteplase in Treating Acute Ischemic Stroke With Diabetes and Admission Hyperglycemia. J Am Heart Assoc. 2024;13(20):e036393. doi:10.1161/JAHA.124.036393

5、Meng X, Li S, Dai H, et al. Tenecteplase vs Alteplase for Patients With Acute Ischemic Stroke: The ORIGINAL Randomized Clinical Trial. JAMA. 2024;332(17):1437-1445. doi:10.1001/jama.2024.14721

6、Zhang R, Liu G, Zhao X, et al. Safety and efficacy of GD-11 in patients with ischaemic stroke: a multicentre, double-blind, randomised, placebo-controlled, phase 2 trial. Stroke Vasc Neurol. Published online August 6, 2024. doi:10.1136/svn-2024-003338

7、Li S, Yang C, Wang W, et al. First-in-human study to assess the safety, tolerability, and pharmacokinetics of intravenous SHPL-49 following single- and multiple-ascending-dose administration in healthy adults. J Pharm Biomed Anal. 2024;249:116314. doi:10.1016/j.jpba.2024.116314

8、Li J, Meng X, Shi FD, et al. Colchicine in patients with acute ischaemic stroke or transient ischaemic attack (CHANCE-3): multicentre, double blind, randomised, placebo controlled trial. BMJ. 2024;385:e079061. Published 2024 Jun 26. doi:10.1136/bmj-2023-079061

9、Li S, Gu HQ, Feng B, et al. RhPro-UK in acute ischemic stroke within 4.5 h of stroke onset trial-2 (the PROST-2 study): Rationale and design of a multicenter, prospective, randomized, open-label, blinded-endpoint, controlled phase 3 non-inferiority trial. Int J Stroke. 2024;19(10):1182-1187. doi:10.1177/17474930241265654

10、Li S, Gu HQ, Li H, et al. Reteplase versus Alteplase for Acute Ischemic Stroke. N Engl J Med. 2024;390(24):2264-2273. doi:10.1056/NEJMoa2400314

11、Xiong Y, Wang L, Pan Y, et al. Tenecteplase versus alteplase for acute ischaemic stroke in the elderly patients: a post hoc analysis of the TRACE-2 trial. Stroke Vasc Neurol. 2025;10(1):112-119. Published 2025 Feb 25. doi:10.1136/svn-2023-003048

12、Fu Y, Wang A, Tang R, et al. Sublingual Edaravone Dexborneol for the Treatment of Acute Ischemic Stroke: The TASTE-SL Randomized Clinical Trial [published correction appears in JAMA Neurol. 2024 Apr 1;81(4):425. doi: 10.1001/jamaneurol.2024.0883.]. JAMA Neurol. Published online February 19, 2024. doi:10.1001/jamaneurol.2023.5716

13、Li S, Wangqin R, Pan Y, et al. Outcomes associated to the time to treatment with intravenous tenecteplase for acute ischaemic stroke: subgroup analysis of the TRACE-2 randomised controlled clinical trial. Stroke Vasc Neurol. 2024;9(6):613-622. Published 2024 Dec 30. doi:10.1136/svn-2023-002694

14、Li S, Gu HQ, Dai H, Lu G, Wang Y. Reteplase versus alteplase for acute ischaemic stroke within 4.5 hours (RAISE): rationale and design of a multicentre, prospective, randomised, open-label, blinded-endpoint, controlled phase 3 non-inferiority trial. Stroke Vasc Neurol. 2024;9(5):568-573. Published 2024 Nov 5. doi:10.1136/svn-2023-003035

15、Li S, Wang X, Jin A, et al. Safety and Efficacy of Reteplase Versus Alteplase for Acute Ischemic Stroke: A Phase 2 Randomized Controlled Trial. Stroke. 2024;55(2):366-375. doi:10.1161/STROKEAHA.123.045193

16、Xiong Y, Wang L, Li G, et al. Tenecteplase versus alteplase for acute ischaemic stroke: a meta-analysis of phase III randomised trials. Stroke Vasc Neurol. 2024;9(4):360-366. Published 2024 Aug 27. doi:10.1136/svn-2023-002396

17、Wang Y, Li S, Pan Y, et al. Tenecteplase versus alteplase in acute ischaemic cerebrovascular events (TRACE-2): a phase 3, multicentre, open-label, randomised controlled, non-inferiority trial [published correction appears in Lancet. 2023 Apr 1;401(10382):1078. doi: 10.1016/S0140-6736(23)00627-X.]. Lancet. 2023;401(10377):645-654. doi:10.1016/S0140-6736(22)02600-9

18、Li S, Wangqin R, Meng X, et al. Tolerability and Pharmacokinetics of Single Escalating and Repeated Doses of CN-105 in Healthy Participants. Clin Ther. 2022;44(5):744-754. doi:10.1016/j.clinthera.2022.03.006

19、Xue M, Li S, Xu M, et al. Antagonism of nicotinic acetycholinergic receptors by CN-105, an apoE-mimetic peptide reduces stroke-induced excitotoxicity. Clin Transl Med. 2022;12(1):e677. doi:10.1002/ctm2.677

20、Li S, Campbell BCV, Schwamm LH, et al. Tenecteplase Reperfusion therapy in Acute ischaemic Cerebrovascular Events-II (TRACE II): rationale and design. Stroke Vasc Neurol. 2022;7(1):71-76. doi:10.1136/svn-2021-001074

21、Li S, Pan Y, Wang Z, et al. Safety and efficacy of tenecteplase versus alteplase in patients with acute ischaemic stroke (TRACE): a multicentre, randomised, open label, blinded-endpoint (PROBE) controlled phase II study. Stroke Vasc Neurol. 2022;7(1):47-53. doi:10.1136/svn-2021-000978

22、Xu J, Wang A, Meng X, et al. Edaravone Dexborneol Versus Edaravone Alone for the Treatment of Acute Ischemic Stroke: A Phase III, Randomized, Double-Blind, Comparative Trial. Stroke. 2021;52(3):772-780. doi:10.1161/STROKEAHA.120.031197

23、Wang Y, Han S, Qin H, et al. Chinese Stroke Association guidelines for clinical management of cerebrovascular disorders: executive summary and 2019 update of the management of high-risk population. Stroke Vasc Neurol. 2020;5(3):270-278. doi:10.1136/svn-2020-000385

24、Li SY, Yang XM, Zhao XQ, et al. Newly detected atrial fibrillation is associated with cortex-involved ischemic stroke. Chin Med J (Engl). 2019;132(17):2053-2058. doi:10.1097/CM9.0000000000000390

25、Zhang X, Li SY, Jing J, et al. Inpatient statin use and stroke recurrence in patients with or without diabetes mellitus. Neurol Res. 2019;41(10):893-899. doi:10.1080/01616412.2019.1642436

26、Liu R, Yang X, Li S, Jiang Y, Wang Y, Wang Y. Modified CHADS2 and CHA2DS2-VASc scores to predict atrial fibrillation in acute ischemic stroke patients. J Clin Neurosci. 2018;51:35-38. doi:10.1016/j.jocn.2018.02.016

27、Liu H, Zheng H, Cao Y, et al. Low- versus Standard-Dose Intravenous Tissue-Type Plasminogen Activator for Acute Ischemic Stroke: An Updated Meta-Analysis. J Stroke Cerebrovasc Dis. 2018;27(4):988-997. doi:10.1016/j.jstrokecerebrovasdis.2017.11.005

28、Yang X, Li S, Zhao X, et al. Atrial fibrillation is not uncommon among patients with ischemic stroke and transient ischemic stroke in China. BMC Neurol. 2017;17(1):207. Published 2017 Dec 4. doi:10.1186/s12883-017-0987-y

29、Liu R, Yang X, Li S, Jiang Y, Wang Y, Wang Y. Novel composite scoring system to predict unknown atrial fibrillation in acute ischemic stroke patients. Brain Res. 2017;1674:36-41. doi:10.1016/j.brainres.2017.08.005

30、Li S, Zhao X, Wang C, et al. Risk factors for poor outcome and mortality at 3 months after the ischemic stroke in patients with atrial fibrillation. J Stroke Cerebrovasc Dis. 2013;22(8):e419-e425. doi:10.1016/j.jstrokecerebrovasdis.2013.04.025

31、Li SY, Zhao XQ, Wang CX, et al. One-year clinical prediction in Chinese ischemic stroke patients using the CHADS2 and CHA2DS2-VASc scores: the China National Stroke Registry. CNS Neurosci Ther. 2012;18(12):988-993. doi:10.1111/cns.12021

32、Li S, Zyang X, Wang Y, Ji H, Du Y, Liu H. DAPT protects brain against cerebral ischemia by down-regulating the expression of Notch 1 and nuclear factor κB in rats. Neurol Sci. 2012;33(6):1257-1264. doi:10.1007/s10072-012-0948-6